The pharmacological inhibition of HO-1 from myeloid areas improved anti-tumor responses and anti-tumor efficacy of OVA vaccine by enhancing the proliferation of CD8+ T cells and preventing the immunosuppressive effects of TME (124). This evidence concerns the gene CD8A and neoplasm.